Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Humana (HUM): which funds own it

Health Care →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow HUM for free
Share

Sections with a free account

18 concentrated managers hold it (−1 vs last quarter); combined they have held more shares for 2 quarters in a row (3 added, 5 trimmed). Its median weight in those portfolios is 2.4%.

Who owns Humana?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Dodge & Cox, 9.5% (13G/A filed May 14, 2026), BlackRock, 7.7% (13G/A filed Apr 17, 2025) and Vanguard Capital Management, 7.6% (13G filed Apr 30, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were Dodge & Cox (9.1% of the shares), BlackRock (8.7%) and Vanguard Capital Management (6.5%).

Which institutions hold the most Humana shares?

Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:

  1. 1. Dodge & Cox: 9.1%
  2. 2. BlackRock: 8.7%
  3. 3. Vanguard Capital Management: 6.5%
  4. 4. Vanguard Portfolio Management: 4.8%
  5. 5. State Street: 4.5%
  6. 6. Pzena Investment Management: 3.7%
  7. 7. Eagle Capital Management: 3.2%
  8. 8. Sessa Capital IM: 3.1%
  9. 9. Massachusetts Financial Services: 3.0%
  10. 10. Geode Capital Management: 2.8%

How much of Humana do institutions own?

The 930 institutions that file 13F reported 98.6% of the shares as of Jun 30, 2026 (not counting 1 position with implausible figures).

Sources:13G/A by Dodge & Cox (May 14, 2026) ↗13G/A by BlackRock (Apr 17, 2025) ↗13G by Vanguard Capital Management (Apr 30, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (Mar 31, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Humana revenue

Humana reported annual revenue of $129.66 billion for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).

Well-known investors holding it

George Soros 13F (Q2 2026)

Concentrated managers
18
All 13F: 930
Consensus
54/100
across 18 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$397.22
+129.1% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (19 → 18): 3 opened · 4 exited = −1

Net flow in the quarter: +$533M (+1.3 M shares) · bought $734M and sold $200MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Accumulation: combined they have held more shares for 2 quarters in a row (3 added, 5 trimmed). It is the combined share count of those still holding it: one large buyer can outweigh many who trimmed.

The set of concentrated managers changed between quarters: with the set as it was then, 20 held it last quarter (the chart point); with today's set, 19 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Other relevant holders

Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.

Largest holders of HUM (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 98.6% of the shares · top 10: 49.5% · in index firms: 32.9% of the institutional total

Share of the stock held by 13F filers

Q2 2026: 98.6%

99.9%90.5%
Q3 2021Q2 2026

Shares reported by the 930 13F filers as of Jun 30, 2026 (not counting 1 position with implausible figures), divided by the shares outstanding on the cover of the company's latest report (Mar 31, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Fundamentals

12-month figures to Mar 31, 2026 · balance sheet as of Mar 31, 2026.

Profitability
Operating margin
1.8%
Net margin
0.8%
ROE
6.1%
Growth
Revenue (TTM)
$137 bn
Revenue growth
14.1%
Net income (TTM)
$1.1 bn
Balance sheet
Net debt / EBITDA
2.9x
Free cash flow (TTM)
$1.3 bn
Quality vs sector
41/100

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 120.8 M

150.9 M0
20162025
1 year
−0.0%
3 years
−4.9%
5 years
−9.2%
Buybacks (FY 2025)
$151M
Share issuance
no data
Stock-based compensation
$241M0.2% of revenue
Dividends paid
$430M

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
1.63
Interest coverage (operating income ÷ interest)
4.3 timesfiscal 2025
Debt due within 12 months
$1.7 bn0.35 times cash and investments
Debt maturities by year (note as of Dec 31, 2025)
  • Year 1$0
  • Year 2$1.0 bn
  • Year 3$993M
  • Year 4$979M
  • Year 5$500M
  • Later$9.0 bn

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
Yes

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Jul 29, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «Humana Elects Paul Smith and Frederick Crawford to Board of Directors»

  • Apr 10, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Dec 16, 2025Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «Humana Announces Insurance Leadership Transition»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow HUM for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow HUM